Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
-
Randomized Controlled Trial
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty.
Forty-three patients who had undergone cementless THA were randomly assigned to receive no osteoactive drug or oral risedronate for 6 months. Postoperative decrease of BMD in the risedronate group was significantly lower than that seen in the control group in zones 1, 2, 3, 6, and 7. ⋯ These outcomes suggested that risedronate might reduce the periprosthetic bone resorption after cementless THA.